Nanoparticle drugs—tiny containers packed with medicine and with the potential to be shipped straight to tumors—were thought to be a possible silver bullet against cancer. However new cancer drugs based on nanoparticles have not improved overall surv ...
Federal health experts have unanimously endorsed a Novartis drug which is expected to become the first lower-cost copy of a biotech drug to reach the U.S. market. A panel of Food and Drug Administration experts ruled that the company's version of Neu ...
Vanderbilt University researcher William Mitchell, M.D., Ph.D., and colleagues in Germany and Canada have demonstrated a method for detecting “cell-free” tumor DNA in the bloodstream. Mitchell believes the technique will be transformative in provid ...
A South Korean medic exposed to Ebola while working in West Africa has been flown to Germany for infectious disease treatment because the patient's anonymity would be better protected there, authorities in Berlin said Saturday. Doctors at Berlin's r ...
The Bristol-Myers Squibb-vs.-Merck match in melanoma immunotherapy is on. Bristol-Myers ($BMY) scored FDA approval for its cancer immunotherapy Opdivo (nivolumab) three months ahead of schedule, setting it up for a head-to-head contest against Merck' ...
Findings of a three-year clinical trial led by University of Cincinnati (UC) transplant researchers suggest that a novel pre-operative drug therapy reduces antibodies in kidney patients with greater success than with traditional methods, with the pot ...
A team of researchers led by Duke Cancer Institute has identified key events that prompt certain cancer cells to develop cancer drug resistance to otherwise lethal therapies. By mapping the specific steps that cells of melanoma, breast cancer, and a ...
An experimental cancer drug may block an important driver for the survival, growth and spread of cancer cells. The first clinical trial of an experimental drug, called pictilisib, found the safety profile to be manageable in cancer patients at dose ...
Results of a small Johns Hopkins Children’s Center study show that hospitalized children given high-dose IV infusions of the antibiotic vancomycin to treat drug-resistant bacterial infections face an increased risk for kidney damage — an often rever ...
Johns Hopkins researchers have developed a sugar-based molecular microcapsule that eliminates the toxicity of an anticancer agent developed a decade ago at Johns Hopkins, called 3-bromopyruvate, or 3BrPA, in studies of mice with implants of human pan ...